Evidence Level
Copper research has primarily focused on deficiency and toxicity rather than therapeutic supplementation. A key clinical finding is zinc-induced copper deficiency: Prasad et al. (1978) and subsequent studies confirmed that zinc supplementation above 50mg/day for extended periods reliably induces copper deficiency, manifesting as anemia, neutropenia, and neurological symptoms. Willis et al. (2005) reported cases of copper deficiency myelopathy mimicking B12 deficiency following chronic zinc supplementation. Current clinical practice recommends 1-2mg supplemental copper whenever zinc exceeds 30mg/day.
Recent studies have explored the relationship between copper and various health conditions. Zhou et al. (2025) conducted a meta-analysis of 13 studies involving 7983 participants, finding that circulating copper levels are significantly higher in osteoarthritis patients compared to healthy individuals, while zinc levels do not differ. Gutiérrez-Guerra et al. (2025) systematically reviewed and meta-analyzed 3 observational studies (n=9059), revealing a modest link between higher dietary copper intake and increased lumbar spine bone mineral density (BMD). Anam et al. (2024) conducted a systematic review and meta-analysis of 41 studies involving 3353 vitiligo cases and 10,638 controls, finding lower serum zinc and copper levels in vitiligo patients compared to controls.
Additionally, Pelosi et al. (2024) found that copper concentrations above 80 mg/kg dry soil can harm earthworms, with sub-lethal effects occurring at lower levels and varying by soil type. These findings highlight the importance of understanding copper's role in human health and its potential environmental impacts.